Efficacy and safefy of Polymyxin B treatment for neutropenic patients suffering from refractory Gram-negative bacterial bloodstream infection / 中华血液学杂志
Chinese Journal of Hematology
;
(12): 484-489, 2023.
Article
in Chinese
| WPRIM
| ID: wpr-984648
ABSTRACT
Objective:
To assess the efficacy and safety of polymyxin B in neutropenic patients with hematologic disorders who had refractory gram-negative bacterial bloodstream infection.Methods:
From August 2021 to July 2022, we retrospectively analyzed neutropenic patients with refractory gram-negative bacterial bloodstream infection who were treated with polymyxin B in the Department of Hematology of the First Affiliated Hospital of the Soochow University between August 2021 to July 2022. The cumulative response rate was then computed.Results:
The study included 27 neutropenic patients with refractory gram-negative bacterial bloodstream infections. Polymyxin B therapy was effective in 22 of 27 patients. The median time between the onset of fever and the delivery of polymyxin B was 3 days [interquartile range (IQR) 2-5]. The median duration of polymyxin B treatment was 7 days (IQR 5-11). Polymyxin B therapy had a median antipyretic time of 37 h (IQR 32-70). The incidence of acute renal dysfunction was 14.8% (four out of 27 cases), all classified as "injury" according to RIFLE criteria. The incidence of hyperpigmentation was 59.3%.Conclusion:
Polymyxin B is a viable treatment option for granulocytopenia patients with refractory gram-negative bacterial bloodstream infections.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Polymyxin B
/
Retrospective Studies
/
Gram-Negative Bacterial Infections
/
Bacteremia
/
Sepsis
/
Fever
/
Anti-Bacterial Agents
Limits:
Humans
Language:
Chinese
Journal:
Chinese Journal of Hematology
Year:
2023
Type:
Article
Similar
MEDLINE
...
LILACS
LIS